Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
29 pending office actions • 23 art units • 29 examiners • 0 of 29 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
Children’S Medical Center Corporation has 1 pending office action in the Medical Devices & Mechanical Engineering technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. ROBINSON, NICHOLAS A is the busiest examiner, managing the pending office action.
The prosecution is highly focused, with a distinct art unit and 1 distinct examiner involved in the company's current filings. Since ROBINSON, NICHOLAS A is the examiner for the 1 pending office action, the company's progress in the Medical Devices & Mechanical Engineering area depends on this individual's review. This concentration allows for a dedicated prosecution strategy but also means that the company's outcomes are tied to the specific tendencies of the examiner.
Practitioners should note that the pending office action represents the entirety of the company's active workload in this profile. The involvement of only a distinct art unit indicates that the subject matter is localized within a specific technical group. Successfully navigating the 1 pending office action will require a thorough understanding of the requirements set forth by ROBINSON, NICHOLAS A and the standards of the art unit involved.
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (7%) |
| §103 only | 12 (41%) |
| §102 only | 1 (3%) |
| §112 only | 1 (3%) |
| Double-patenting + other | 3 (10%) |
| Multi-statute (no §101) | 10 (34%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROWN, SETH RICHARD | 1 | 48.9% | +44.3% |
| ZEMAN, ROBERT A | 1 | 54.3% | +27.7% |
| BUI, PHUONG T | 1 | 81.2% | +23.2% |
| XIE, XIAOZHEN | 1 | 56.6% | +65.8% |
| MILLER, DALE R | 1 | 62.4% | +17.5% |
| EPSTEIN, TODD MATTHEW | 1 | 60.9% | +43.4% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.1% | +39.3% |
| GHERBI, SUZETTE JAIME J | 1 | 85.0% | +8.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030473 | ENGINEERING-DESIGN-BASED WORKFLOW FOR VALVE RECONSTRUCTION | GHERBI, SUZETTE JAIME J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17371017 | MYBPC3 POLYPEPTIDES AND USES THEREOF | DHAR, MATASHA | 107d overdue |
| 17422638 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | CREWS, JARET JAMES | 53d overdue |
| 17312248 | GENOMIC REARRANGEMENTS ASSOCIATED WITH PROSTATE CANCER AND METHODS OF USING THE SAME | SISSON, BRADLEY L | 42d overdue |
| 17759045 | IMMUNOLOGICALLY OPTIMIZED BOTULINUM TOXIN LIGHT CHAIN VARIANTS | DEVI, SARVAMANGALA | 36d overdue |
| 18268477 | IMPROVED RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A AND USES THEREOF | PAGUIO FRISING, MICHELLE F | 34d |
| 18579325 | EXTRACHROMOSOMAL CIRCULAR DNA AS AN IMMUNOSTIMULANT AND BIOMARKER FOR DISEASE | BUI, PHUONG T | — |
| 18577206 | SYSTEMS AND METHODS FOR DELIVERY BASED ON SUPRAMOLECULAR NANOSTRUCTURES | XIE, XIAOZHEN | — |
| 18396181 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MILLER, DALE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278394 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | BENAVIDES, JENNIFER ANN | 27d |
| 18268477 | IMPROVED RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A AND USES THEREOF | PAGUIO FRISING, MICHELLE F | 34d |
| 18282215 | ENGINEERED BOTULINUM NEUROTOXIN A PROTEASE DOMAIN WITH IMPROVED EFFICACY | EPSTEIN, TODD MATTHEW | 82d |
| 19003564 | SOFT BRACES TO PREVENT INJURY TO A JOINT OR BODY SEGMENT | BROWN, SETH RICHARD | — |
| 18799550 | PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASE | ZEMAN, ROBERT A | — |
| 18579325 | EXTRACHROMOSOMAL CIRCULAR DNA AS AN IMMUNOSTIMULANT AND BIOMARKER FOR DISEASE | BUI, PHUONG T | — |
| 18577206 | SYSTEMS AND METHODS FOR DELIVERY BASED ON SUPRAMOLECULAR NANOSTRUCTURES | XIE, XIAOZHEN | — |
| 18396181 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MILLER, DALE R | — |
| Art Unit | Apps |
|---|---|
| 3771 | 2 |
| 1633 | 2 |
| 1691 | 2 |
| 3786 | 1 |
| 1663 | 1 |
| 4100 | 1 |
| 1699 | 1 |
| 1672 | 1 |
| 1675 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19003564 | SOFT BRACES TO PREVENT INJURY TO A JOINT OR BODY SEGMENT | BROWN, SETH RICHARD | 3786 | §103 | Final Rejection | — | Pending | Dec 27, 2024 |
| 18799550 | PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASE | ZEMAN, ROBERT A | — | §103 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18579325 | EXTRACHROMOSOMAL CIRCULAR DNA AS AN IMMUNOSTIMULANT AND BIOMARKER FOR DISEASE | BUI, PHUONG T | 1663 | §102§103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18577206 | SYSTEMS AND METHODS FOR DELIVERY BASED ON SUPRAMOLECULAR NANOSTRUCTURES | XIE, XIAOZHEN | — | §102§112 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18396181 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MILLER, DALE R | 4100 | §102§103 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18282215 | ENGINEERED BOTULINUM NEUROTOXIN A PROTEASE DOMAIN WITH IMPROVED EFFICACY | EPSTEIN, TODD MATTHEW | 1699 | §102 | Non-Final OA | 82d | Pending | Sep 14, 2023 |
| 18281540 | POLYSACCHARIDE ADJUVANTS FOR VIRUS VACCINES | CHEN, STACY BROWN | 1672 | §102§103 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18278394 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §103Other | Final Rejection | 27d | Pending | Aug 22, 2023 |
| 18268477 | IMPROVED RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A AND USES THEREOF | PAGUIO FRISING, MICHELLE F | 1651 | §102§103 | Non-Final OA | 34d | Pending | Jun 20, 2023 |
| 18030473 | ENGINEERING-DESIGN-BASED WORKFLOW FOR VALVE RECONSTRUCTION | GHERBI, SUZETTE JAIME J | 3774 | §103 | Non-Final OA | — | Pending | Apr 05, 2023 |
| 18030467 | COMPUTATIONAL PLANNING OF SURGICAL RECONSTRUCTION | DIETZ, NOE ROBERT | 3791 | §103 | Final Rejection | 28d overdue | Pending | Apr 05, 2023 |
| 18168131 | FORCE-CONTROLLED NANOSWITCH ASSAYS FOR SINGLE-MOLECULE DETECTION IN COMPLEX BIOLOGICAL FLUIDS | HORLICK, KENNETH R | — | §112DP | Non-Final OA | — | Pending | Feb 13, 2023 |
| 18014901 | GUIDING BLOOD PRODUCT ADMINISTRATION TO MITIGATE BLEEDING RISK | FRITCHMAN, REBECCA M | 1758 | §101§103§112 | Non-Final OA | — | Pending | Jan 06, 2023 |
| 17878406 | INTRACORPOREAL SUTURE TYING | JAFFRI, ZEHRA | 3771 | §103 | Final Rejection | 5d overdue | Pending | Aug 01, 2022 |
| 17759045 | IMMUNOLOGICALLY OPTIMIZED BOTULINUM TOXIN LIGHT CHAIN VARIANTS | DEVI, SARVAMANGALA | 1645 | §102§112 | Final Rejection | 36d overdue | Pending | Jul 19, 2022 |
| 17855719 | TISSUE FASTENING | SCHERBEL, TODD J | 3771 | §103 | Non-Final OA | 33d | Pending | Jun 30, 2022 |
| 17777659 | STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY | CHATTIN, AMY MARIE | 1643 | §103 | Final Rejection | 91d overdue | Pending | May 18, 2022 |
| 17769536 | METHODS FOR MULTI-FOCAL IMAGING FOR MOLECULAR PROFILING | CROW, ROBERT THOMAS | 1600 | §103§112DP | Non-Final OA | — | Pending | Apr 15, 2022 |
| 17637305 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | PETRASH, HILARY ANN | 1644 | §102§103§112DP | Final Rejection | — | Pending | Feb 22, 2022 |
| 17635409 | LARGE SCALE PRODUCTION OF EXOSOME MIMETICS AND USES THEREOF | MEJIAS, SAMANTHA LEE | 1618 | §103 | Non-Final OA | 14d | Pending | Feb 15, 2022 |
| 17486855 | ABCB5(+) STEM CELLS FOR TREATING OCULAR DISEASE | FOX, ALLISON M | 1633 | §101§112 | Non-Final OA | — | Pending | Sep 27, 2021 |
| 17422638 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | CREWS, JARET JAMES | 1691 | §103§112 | Final Rejection | 53d overdue | Pending | Jul 13, 2021 |
| 17371017 | MYBPC3 POLYPEPTIDES AND USES THEREOF | DHAR, MATASHA | 1632 | §103§112 | Final Rejection | 107d overdue | Pending | Jul 08, 2021 |
| 17312248 | GENOMIC REARRANGEMENTS ASSOCIATED WITH PROSTATE CANCER AND METHODS OF USING THE SAME | SISSON, BRADLEY L | 1682 | §103§112 | Non-Final OA | 42d overdue | Pending | Jun 09, 2021 |
| 17275266 | NANOPARTICLE FORMULATIONS AND METHODS OF THEIR USE | MACH, ANDRE | 1615 | §103 | Non-Final OA | — | Pending | Mar 11, 2021 |
| 17053752 | MESENCHYMAL STROMAL CELL EXOSOME-TREATED MONOCYTES AND USES THEREOF | WESTON, ALYSSA G | 1633 | §102§103 | Non-Final OA | — | Pending | Nov 06, 2020 |
| 16979084 | COMPOSITIONS AND METHODS FOR MUTATIONS ASSOCIATED WITH SUDDEN UNEXPECTED DEATH IN PEDIATRICS | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 128d overdue | Pending | Sep 08, 2020 |
| 16639474 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | — | Pending | Feb 14, 2020 |
| 16628162 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | BEANE, RANDALL L | 1654 | §103 | Final Rejection | — | Pending | Jan 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial